Intravenous Injection of Clinical Grade Human MSCs after Experimental Stroke: Functional Benefit and Microvascular Effect

Stroke is the leading cause of disability in adults. Many current clinical trials use intravenous (IV) administration of human bone marrow-derived mesenchymal stem cells (BM-MSCs). This autologous graft requires a delay for ex vivo expansion of cells. We followed microvascular effects and mechanisms...

Full description

Bibliographic Details
Main Authors: Anaïck Moisan, Isabelle Favre, Claire Rome, Florence De Fraipont, Emmanuelle Grillon, Nicolas Coquery, Hervé Mathieu, Virginie Mayan, Bernadette Naegele, Marc Hommel, Marie-Jeanne Richard, Emmanuel Luc Barbier, Chantal Remy, Olivier Detante
Format: Article
Language:English
Published: SAGE Publishing 2016-12-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368916X691132